Skip to main content

Market Overview

Morgan Stanley Says Buy Repare Therapeutics, Sees Nearly 60% Upside

Morgan Stanley Says Buy Repare Therapeutics, Sees Nearly 60% Upside

Repare Therapeutics Inc. (NASDAQ: RPTX), which is working to develop precision oncology therapies by leveraging synthetic lethal interactions in cancer, went public in June.

The Repare Analyst: Jeffrey Hung initiated coverage of Repare Theraupetics with an Overweight rating and $37 price target.

The Repare Approach: Repare is “developing drugs targeting one gene that is a synthetic lethal pair with another already mutated in cancer cells,” Hung said in the initiation note.

RP-3500, the company’s lead drug candidate, is expected to enter Phase 1/2 studies in the third quarter, the analyst said. Using their screening platform SNIPRx, Repare identified 19 additional (STEP2) genes in cancer that could be treated with RP-3500, he said.

This increased the treatable patient population from 2% to 10%, Hung said.

Repare’s SNIPRx screening platform “identifies novel targets,” which increases the upside potential for the stock.

RPTX Price Action: Shares of Repare Therapeutics ended Tuesday’s session down 3.33% at $23.21.


Related Articles (RPTX)

View Comments and Join the Discussion!

Posted-In: Analyst Color Price Target Initiation Analyst Ratings

Latest Ratings

SVLake StreetInitiates Coverage On20.0
CLSDJMP SecuritiesMaintains9.0
WPCJP MorganUpgrades88.0
BRKRCleveland ResearchUpgrades
NTRRaymond JamesDowngrades82.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at